PMID- 32855778
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231111
IS  - 2008-126X (Print)
IS  - 2228-7442 (Electronic)
IS  - 2008-126X (Linking)
VI  - 11
IP  - 2
DP  - 2020 Mar-Apr
TI  - Drug Interactions of Psychiatric and COVID-19 Medications.
PG  - 185-200
LID - 10.32598/bcn.11.covid19.2500.1 [doi]
AB  - INTRODUCTION: Coronavirus disease 2019 (COVID-19) has become a pandemic with 
      1771514 cases identified in the world and 70029 cases in Iran until April 12, 
      2020. The co-prescription of psychotropics with COVID-19 medication is not 
      uncommon. Healthcare providers should be familiar with many Potential Drug-Drug 
      Interactions (DDIs) between COVID-19 therapeutic agents and psychotropic drugs 
      based on cytochrome P450 metabolism. This review comprehensively summarizes the 
      current literature on DDIs between antiretroviral drugs and 
      chloroquine/hydroxychloroquine, and psychotropics, including antidepressants, 
      antipsychotics, mood stabilizers, and anxiolytics. METHODS: Medical databases, 
      including Google Scholar, PubMed, Web of Science, and Scopus were searched to 
      identify studies in English with keywords related to psychiatric disorders, 
      medications used in the treatment of psychiatric disorders and COVID-19 
      medications. RESULTS: There is a great potential for DDIs between psychiatric and 
      COVID-19 medications ranging from interactions that are not clinically apparent 
      (minor) to those that produce life-threatening adverse drug reactions, or loss of 
      treatment efficacy. The majority of interactions are pharmacokinetic interactions 
      via the cytochrome P450 enzyme system. CONCLUSION: DDIs are a major concern in 
      the comorbidity of psychiatric disorders and COVID-19 infection resulting in the 
      alteration of expected therapeutic outcomes. The risk of toxicity or lack of 
      efficacy may occur due to a higher or lower plasma concentration of medications. 
      However, psychiatric medication can be safely used in combination with COVID-19 
      pharmacotherapy with either a wise selection of medication with the least 
      possibility of interaction or careful patient monitoring and management.
CI  - Copyright(c) 2020 Iranian Neuroscience Society.
FAU - Mohebbi, Niayesh
AU  - Mohebbi N
AUID- ORCID: 0000-0002-1420-7286
AD  - Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical 
      Sciences, Tehran, Iran.
AD  - Research Center for Rational Use of Drugs; Tehran University of Medical Sciences, 
      Tehran, Iran.
FAU - Talebi, Ali
AU  - Talebi A
AUID- ORCID: 0000-0003-2936-453X
AD  - Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical 
      Sciences, Tehran, Iran.
FAU - Moghadamnia, Marjan
AU  - Moghadamnia M
AUID- ORCID: 0000-0002-0459-1042
AD  - Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical 
      Sciences, Tehran, Iran.
FAU - Nazari Taloki, Zahra
AU  - Nazari Taloki Z
AUID- ORCID: 0000-0002-7919-9192
AD  - Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical 
      Sciences, Tehran, Iran.
FAU - Shakiba, Alia
AU  - Shakiba A
AUID- ORCID: 0000-0001-5720-8900
AD  - Department of Psychiatry, Roozbeh Hospital, Tehran University of Medical 
      Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200427
PL  - Iran
TA  - Basic Clin Neurosci
JT  - Basic and clinical neuroscience
JID - 101575211
PMC - PMC7368108
OTO - NOTNLM
OT  - Antidepressants
OT  - Antipsychotics
OT  - Anxiolytics
OT  - COVID-19
OT  - Chloroquine
OT  - Drug interaction
EDAT- 2020/08/29 06:00
MHDA- 2020/08/29 06:01
PMCR- 2020/03/01
CRDT- 2020/08/29 06:00
PHST- 2020/04/16 00:00 [received]
PHST- 2020/04/25 00:00 [revised]
PHST- 2020/04/26 00:00 [accepted]
PHST- 2020/08/29 06:00 [entrez]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2020/08/29 06:01 [medline]
PHST- 2020/03/01 00:00 [pmc-release]
AID - BCN-11-185 [pii]
AID - 10.32598/bcn.11.covid19.2500.1 [doi]
PST - ppublish
SO  - Basic Clin Neurosci. 2020 Mar-Apr;11(2):185-200. doi: 
      10.32598/bcn.11.covid19.2500.1. Epub 2020 Apr 27.